Follow the entities shaping the evidence.

… blood samples collected from patients treated with monotherapy CX-801.Results PK analysis demonstrated dose-proportional exposure of …

…carcinoma (HNSCC)—which shares histology but responds poorly to PD-1 inhibitors—may offer new insights into CSCC pathogenesis and immune respon…

…ent strategies are required to achieve durable tumor rejection. Odronextamab, a CD20xCD3 bispecific antibody, has been approved in the EU fo…

…erapeutic index of ZW270 in vivo compared to wild type IL-12Fc. ZW270 was well tolerated in non-human primates (>30mg/kg) with slow e…

…pproval Studies involving animals were approved by the IACUC at NC State University (23-126).Abstract 884 Figure 1Individual tumor growth curves fo…

… Our Lab previously showed that a small molecule STING agonist (ADU-S100), can turn on the pathway and improve survival in mouse GBM mod…

…as an immune checkpoint inhibitor and tumor-homing molecule for cancer treatment. Nat Commun. 2022;11:1137.Ethics Approval All procedu…

…g, known as inspiratory muscle training (IMT), in patients with cardiovascular disease, both exercise forms are regularly used in cardiac rehabilitati…

…of origin (ToO) will include bladder, breast, colorectal, lung, melanoma, oesophageal, ovarian, pancreatic, prostate and renal. Particip…

…ngs (KES) 1920 (46 Intl$) with IPT and KES 1350 (31 Intl$) with fluoxetine. Absenteeism dropped in both treatment arms, by 1.5 days per mo…

…r refractory HRF patients with good NIV compliance who received acetazolamide. No evidence of harm demonstrated. If instituted sooner, it mig…

…s (pneumothorax: mean 66 (SD 20); PE: 71 (SD = 17)). PPVs were: pneumothorax 80% (132/165), PE 85.3% (515/604), and PE with cor pulmonale 93…